Bayer CropScience FY26: Q4 PBT +83% QoQ, dividend Rs 60

Key Q4FY26 takeaways

Bayer CropScience reported a steady rise in total income in Q4FY26, alongside a sharp sequential jump in profitability. Total income for the quarter stood at INR 11,474 million, up 2.25% QoQ from INR 11,221 million and up 5.90% YoY from INR 10,835 million. Profit before tax (PBT) rose to INR 2,064 million, marking 82.65% QoQ growth from INR 1,130 million and 22.93% YoY growth from INR 1,679 million. Net profit for Q4FY26 came in at INR 1,621 million, up 69.38% QoQ from INR 957 million, and 13.12% YoY from INR 1,433 million. Total comprehensive income for the quarter was INR 1,539 million. The numbers indicate a quarter where profit growth outpaced income growth.

FY26 income trend and comprehensive income

On a full-year basis, the company reported annual total income of INR 57,700 million for FY26, representing 3.16% growth over FY25. For total comprehensive income, FY26 came in at INR 6,771 million, up 20.31% from INR 5,628 million in FY25. The gap between total income growth and comprehensive income growth highlights that FY26’s bottom-line trajectory was stronger than the top-line expansion. The company also reported basic and diluted EPS of INR 153.35 for FY26, compared with INR 126.38 in FY25.

Dividend: final payout recommendation and interim dividend history

Bayer CropScience’s Board of Directors recommended a final dividend of INR 60 per share for the year ended March 31, 2026. The recommended final dividend aggregates to INR 2,697 million for 44,942,092 equity shares of face value INR 10 each. Separately, the board meeting held on November 07, 2025, declared an interim dividend of INR 90 per equity share for the financial year ending March 31, 2026, amounting to INR 4,045 million. These disclosures outline the company’s stated dividend actions for FY26.

Other operating and profit data points cited

The provided data set also lists additional revenue-from-operations and PBT figures across periods, indicating variability across quarters. Revenue from operations is stated at INR 11,062 million, compared with INR 10,574 million in Q3FY25. Alongside this, PBT is stated at INR 1,130 million, compared with INR 336 million in Q3FY25. Another data point lists revenue from operations of INR 15,534 million, compared with INR 17,382 million in Q2FY25, while PBT is stated at INR 2,003 million, compared with INR 1,901 million in Q2FY25. These figures are presented as period-on-period comparisons and help frame how earnings and sales have moved across different quarters.

Q1FY26 performance noted for Bayer CropScience

For Q1FY26, Bayer CropScience reported revenue from operations of INR 19,146 million, compared with INR 16,314 million in Q1FY25. PBT for the quarter stood at INR 3,352 million, compared with INR 3,158 million in Q1FY25. The data suggests that the year began with higher revenue from operations and a modest increase in PBT year-on-year, before the later-quarter movements described above.

Half-year comparison data included in the disclosures

The information provided also includes a half-year comparison: revenue from operations of INR 33,688 million compared with INR 33,568 million for H1FY24. PBT for H1FY25 is shown at INR 5,059 million, compared with INR 7,118 million for H1FY24. The same set also includes a standalone reference to PBT of INR 3,823 million without an associated period label. These numbers, as stated, indicate that while revenue was broadly flat in the half-year comparison, PBT was lower versus the earlier period referenced.

Bayer Group Q1 2026: sales, earnings, and cash flow context

Separately from the India subsidiary’s rupee disclosures, the Bayer Group reported Q1 2026 performance (release date May 12, 2026). Group sales were EUR 13,405 million in Q1 2026 (Q1 2025: EUR 13,738 million), with +4.1% growth on a currency- and portfolio-adjusted basis and -2.4% on a reported basis. The company disclosed a negative currency effect of EUR 886 million on sales. EBITDA before special items increased 9.0% to EUR 4,453 million. Core earnings per share rose to EUR 2.71, up 12.9%, with the company stating that EUR 0.40 came from licensing resolution income and EUR 0.10 from tail-end divestment income in Pharma. Net income improved to EUR 2,763 million.

Crop Science division performance at the global level

Within Bayer’s Crop Science division, sales in Q1 2026 were EUR 7,558 million (Q1 2025: EUR 7,580 million), with -0.3% reported change and +6.8% on an Fx and portfolio-adjusted basis. EBITDA before special items for Crop Science increased 17.9% to EUR 3,014 million (Q1 2025: EUR 2,557 million). EBIT came in at EUR 2,277 million (Q1 2025: EUR 1,386 million). Bayer attributed the division’s sales and earnings improvement to gains in Soybean Seed and Traits following the resolution of a licensing agreement, and growth in Corn Seed and Traits.

Market reaction and cited trading indicators

A market report cited that Bayer AG’s results beat expectations and that shares rose more than 6% following the update, alongside commentary that EBITDA before special items exceeded a company-provided consensus estimate of EUR 3.93 billion. For the India-listed Bayer CropScience, the stock was cited at INR 4,489.10 on the NSE as of May 11, 2026, down 2.62% from the previous close. The same source cited trailing twelve-month EPS in the range of INR 131.84 to INR 135.48, implying a price-to-earnings range of 34.55 to 37.62 based on that price and EPS band.

Outlook and what investors may track next

Bayer said it confirmed its currency-adjusted Group outlook and, applying exchange rates as of March 31, 2026, expects full-year 2026 sales of EUR 44,500 million to EUR 46,500 million, EBITDA before special items of EUR 9,400 million to EUR 9,900 million, and core EPS of EUR 4.10 to EUR 4.60. It also disclosed Q1 free cash flow of minus EUR 2,300 million, linked to settlement payments totaling about EUR 2,000 million for PCB and glyphosate, and reported net financial debt of EUR 32,500 million (Dec. 31, 2025: EUR 29,800 million; Mar. 31, 2025: EUR 34,300 million). For India-focused investors tracking Bayer CropScience, near-term attention typically centers on dividend shareholder approvals and record dates, and on how quarterly profit movements compare with the FY26 EPS trend already disclosed.

Summary table of key figures (as disclosed)

Bayer CropScience (India) highlights

Bayer Group (global) Q1 2026 snapshot